Patents by Inventor Stefan Knackmuss
Stefan Knackmuss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220041717Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCMType: ApplicationFiled: October 26, 2021Publication date: February 10, 2022Inventors: Thorsten ROSS, Ivica FUCEK, Kristina ELLWANGER, Michael WEICHEL, Uwe REUSCH, Stefan KNACKMUSS, Erich RAJKOVIC, Martin TREDER
-
Patent number: 11180558Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCM.Type: GrantFiled: July 23, 2019Date of Patent: November 23, 2021Assignee: Affimed GMBHInventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Patent number: 11167029Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.Type: GrantFiled: October 19, 2017Date of Patent: November 9, 2021Assignee: AFFIMED GMBHInventors: Martin Treder, Uwe Reusch, Jens-Peter Marschner, Stefan Knackmuss
-
Publication number: 20210024654Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: March 18, 2020Publication date: January 28, 2021Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 10626190Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: October 27, 2017Date of Patent: April 21, 2020Assignee: Amphivena Therapeutics, Inc.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Publication number: 20190345249Abstract: The invention relates to a multispecific antigen-binding molecule specifically binding to CD16A and consisting of two polypeptide chains, wherein each polypeptide chain comprises at least four variable domains from the N-terminus to the C-terminus in the order: VH_BCMA-VL_CD16A-VH_CD16A-VL_BCMType: ApplicationFiled: July 23, 2019Publication date: November 14, 2019Inventors: Thorsten Ross, Ivica Fucek, Kristina Ellwanger, Michael Weichel, Uwe Reusch, Stefan Knackmuss, Erich Rajkovic, Martin Treder
-
Patent number: 10273309Abstract: This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3. Further described are highly cytotoxic EGFRvIII/CD3 bispecific tandem diabody for recruiting T cells to specifically and potently kill several types of solid tumor cancer.Type: GrantFiled: February 4, 2016Date of Patent: April 30, 2019Assignee: AFFEMED GMBHInventors: Kristina Ellwanger, Uwe Reusch, Ivica Fucek, Stefan Knackmuss, Vera Molkenthin, Melvyn Little, Eugene Zhukovsky
-
Publication number: 20180291113Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: October 27, 2017Publication date: October 11, 2018Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 10066015Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.Type: GrantFiled: August 6, 2015Date of Patent: September 4, 2018Assignee: Affirmed GmbHInventors: Eugene Zhukovsky, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala McAleese-Eser
-
Publication number: 20180085456Abstract: Described is a combination therapy of (i) a multifunctional antibody having specificity for CD30 and CD16A and (ii) an anti-PD-1 antibody for the treatment of a tumor, in particular Hodgkin lymphoma.Type: ApplicationFiled: October 19, 2017Publication date: March 29, 2018Inventors: Martin TREDER, Uwe REUSCH, Jens-Peter MARSCHNER, Stefan KNACKMUSS
-
Patent number: 9803029Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: November 10, 2015Date of Patent: October 31, 2017Assignee: AMPHIVENA THERAPEUTICS, INC.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Patent number: 9701750Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: GrantFiled: April 20, 2015Date of Patent: July 11, 2017Assignee: Affimed GmbHInventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch
-
Publication number: 20160361413Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.Type: ApplicationFiled: May 10, 2016Publication date: December 15, 2016Applicant: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
-
Publication number: 20160194409Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: November 10, 2015Publication date: July 7, 2016Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 9365647Abstract: The invention relates to a method of modulating concentration of Alzheimer's Disease (AD) relevant proteins amyloid precursor protein (APP), beta (?) and gamma (?) secretases and amyloid beta peptide (A?), and also relates to a method of reducing A? shedding. Furthermore, this invention extends to a compound for use in the treatment of AD, and also to a method of treating AD.Type: GrantFiled: September 19, 2012Date of Patent: June 14, 2016Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURGInventors: Stefan Franz Thomas Weiss, Katarina Jovanovic, Danielle Gonsavles, Bianca Da Costa Dias, Stefan Knackmuss, Uwe Reusch, Melvyn Little, Marc Saul Weinberg
-
Publication number: 20160152728Abstract: This application describes binding proteins that specifically bind to EGFRvIII and multispecific binding proteins that specifically bind to EGFRvIII and CD3. Further described is a multispecific tandem diabody that binds to EGFRvIII and CD3.Type: ApplicationFiled: February 4, 2016Publication date: June 2, 2016Inventors: Kristina ELLWANGER, Uwe REUSCH, Ivica FUCEK, Stefan KNACKMUSS, Vera MOLKENTHIN, Melvyn LITTLE, Eugene ZHUKOVSKY
-
Publication number: 20160039934Abstract: The invention relates to a humanized CD3 binding site, which comprises (a) a variable heavy chain domain (VH) as depicted in SEQ ID NO:8 and a variable light chain domain (VL) as depicted in SEQ ID NO:3; or (b) a variable heavy chain domain (VH) as depicted in SEQ ID NO:9 and a variable light chain domain (VL) as depicted in SEQ ID NO:4, or c) a variable heavy chain domain (VH) as depicted in SEQ ID NO:7 and a variable light chain domain (VL) as depicted in SEQ ID NO:2; or (d) a variable heavy chain domain (VH) as depicted in SEQ ID NO:6 and a variable light chain domain (VL) as depicted in SEQ ID NO:1. The CD3 binding sites have an increased stability, while the binding affinity has been retained due to mutations at positions VH111 and VL49.Type: ApplicationFiled: August 6, 2015Publication date: February 11, 2016Inventors: Eugene ZHUKOVSKY, Melvyn Little, Stefan Knackmuss, Uwe Reusch, Kristina Ellwanger, Ivica Fucek, Michael Weichel, Markus Eser, Fionnuala Mcaleese-Eser
-
Publication number: 20160002333Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: ApplicationFiled: March 9, 2015Publication date: January 7, 2016Inventors: Kristina ELLWANGER, Luke EVNIN, Judith A. FOX, Ivica FUCEK, Jeanmarie GUENOT, Stefan KNACKMUSS, Lori KUNKEL, Melvyn LITTLE, Vera MOLKENTHIN, Erich RAJKOVIC, Uwe REUSCH, Claudia WALL, Michael WEICHEL, Eugene ZHUKOVSKY
-
Patent number: 9212225Abstract: Described herein are binding proteins that specifically bind to human CD33, and in particular to bispecific binding proteins that specifically bind to human CD33 and human CD3. Also described herein are bispecific tandem diabodies that bind to CD33 and CD33, and their uses for immunotherapy of CD33+ cancers, diseases and conditions such as acute myeloid leukemia (AML).Type: GrantFiled: March 9, 2015Date of Patent: December 15, 2015Assignee: AMPHIVENA THERAPEUTICS, INC.Inventors: Kristina Ellwanger, Luke Evnin, Judith A. Fox, Ivica Fucek, Jeanmarie Guenot, Stefan Knackmuss, Lori Kunkel, Melvyn Little, Vera Molkenthin, Erich Rajkovic, Uwe Reusch, Claudia Wall, Michael Weichel, Eugene Zhukovsky
-
Publication number: 20150218275Abstract: The present invention relates to binding molecules that specifically bind to the human Fc gamma receptor expressed on the surface of natural killer (NK) cells and macrophages (i.e. Fc?RIIIA), and in particular binding molecules that specifically bind the A form Fc?RIII but do not bind to the B form of Fc?RIII, as well as to the use of such binding molecules in the diagnosis and treatment of disease. The invention further extends to polynucleotides encoding such binding molecules, host cells comprising such polynucleotides and methods of producing binding molecules of the invention using such host cells.Type: ApplicationFiled: April 20, 2015Publication date: August 6, 2015Inventors: Karin Hoffmann, Sergey Kipriyanov, Stefan Knackmuss, Fabrice Le Gall, Melvyn Little, Uwe Reusch